about
Combination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft model4-(1,2-diarylbut-1-en-1-yl)isobutyranilide derivatives as inhibitors of topoisomerase II.MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis.Class II phosphoinositide 3-kinase C2β regulates a novel signaling pathway involved in breast cancer progression.Resistance to glucose starvation as metabolic trait of platinum-resistant human epithelial ovarian cancer cells.Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.New class of squalene-based releasable nanoassemblies of paclitaxel, podophyllotoxin, camptothecin and epothilone A.Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenograftsOvarian carcinoma tumor-initiating cells have a mesenchymal phenotype.A high-throughput screening of a chemical compound library in ovarian cancer stem cells.Heteronanoparticles by self-Assembly of Doxorubicin and Cyclopamine Conjugates.Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts.Recent Insights into Mucinous Ovarian Carcinoma.Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic AlterationsOvercoming platinum-acquired resistance in ovarian cancer patient-derived xenografts
P50
Q27302940-CC070028-420E-4F3C-B1C0-BBC3270BB54AQ36003021-F596A056-B45B-4D65-8949-F639A6AAB22AQ36381924-1C366B25-C3C5-489B-9D85-B4CEF45C93A8Q37109753-4962C30A-4728-4445-AC4E-F8CAACEB0EEBQ37701616-8DF828DF-2A34-4EDA-98DE-08E78190908AQ37702541-56F03B3D-B605-4E62-AD3B-B61689BCC5F4Q38969552-5F340EC6-7CB6-482E-AEF0-3C69E16DF545Q42344756-534D2E7B-45BE-42F7-9F47-07D4B7898404Q47834312-96E4E883-BB83-436E-AB07-3A3806791416Q49798198-5F5C94FB-8A63-46A2-891A-9D0E92073798Q49838224-A66AE7CC-33D6-484F-91CA-B557B40609C0Q55181360-8DFF4310-79A1-4EC2-927D-468E073D6283Q55609057-289244C2-2605-4DE0-9A1C-1035FE44B70CQ57819003-1FDBFBF8-EF97-482B-A6E0-7D1286CD9FAFQ93148158-07FEADE3-869E-494D-85D1-1CEE5AD0502F
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0003-1705-186X
@en
name
Francesca Ricci
@ast
Francesca Ricci
@en
Francesca Ricci
@es
Francesca Ricci
@nl
type
label
Francesca Ricci
@ast
Francesca Ricci
@en
Francesca Ricci
@es
Francesca Ricci
@nl
prefLabel
Francesca Ricci
@ast
Francesca Ricci
@en
Francesca Ricci
@es
Francesca Ricci
@nl
P106
P1153
7103269532
P31
P496
0000-0003-1705-186X